CTLA4 and hepatocellular carcinoma: In recent years, immunotherapy has brought about a significant and lasting change in the field of systemic therapy for patients with advanced HCC, as the results of numerous phase 2 and 3 trials have shown promising results with the administration of PD-1, PD-L1 and CTLA-4 ICIs.